Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Art of Investing -- Ignore unavailable to you. Want to Upgrade?

To: Sun Tzu who wrote (8243)	3/15/2024 7:55:29 PM
From: russet	Read Replies (1) \| Respond to of 10749

Relative to placebo, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts. Sotagliflozin was associated with similar risks of severe hypoglycemia between the two cohorts. It is poorly worded therefore can be misinterpreted. They are saying the drug worked well in the new study testing CKD cohort (people with diabetes and chronic kidney disease) without hurting the patients (good safety profile, just like all the other studies). A problem would have arisen if the drug hurt these ill CKD patients, but it didn't, and it lowered the patients blood glucose levels, so success and safe.